Cite

HARVARD Citation

    Kang, J. et al. (2018). Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer. Thoracic cancer. 9 (9), pp. 1093-1103. [Online]. 
  
Back to record